References

Cancer Statistics

A8

Vrinten, C et al. What do people fear about cancer? A systematic review and meta-synthesis of cancer fears in the general population. Psychooncology. 2017 Aug;26(8):1070-1079. doi: 10.1002/pon.4287. Epub 2016 Oct 6.

Genetics and Cancer

B11

Zhang, L et al. Population genomic screening of all young adults in a healthcare system: a cost-effectiveness analysis. Genet Med. 2019 Sep;21(9):1958-1968. doi: 10.1038/s41436-019-0457-6. Epub 2019 Feb 18.

Kim, G et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 1;20(19):4994-5000.doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5.

B16

Gutierrez, ME et al. 2019. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. JCO Precis Oncol. 2019 Dec 6;3:PO.19.00274. doi: 10.1200/PO.19.00274. eCollection 2019

Gutierrez ME et al. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Clin Lung Cancer. 2017 Apr 13. pii: S1525-7304(17)30109-2.

B18

Zehir A et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703-713

Chakravarty, D et al. Review: Clinical cancer genomic profiling. Nat Rev Genet. 2021 Mar 24

Massard C et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017 Jun;7(6):586-595

Cobain EF et al. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncol. 2021 Feb 25.

B19

Reitsma, M et al. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective. J Manag Care Spec Pharm. 2019 May;25(5):601-611. doi: 10.18553/jmcp.2019.18309. Epub 2019 Jan 11.

B20

Siegel, RL et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.

Smalley, P. Testing, 1, 2, 3: Exploring the impact of cancer genomic profiling on insured mortality. Society of Actuaries online magazine, The Actuary, August/September 2019.

B21

Manchanda, R et al. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. J Natl Cancer Inst. 2018 Jul 1;110(7):714-725. doi: 10.1093/jnci/djx265.

B22

Tsimberidou, AM et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 Dec 30;12(1):145. doi: 10.1186/s13045-019-0835-1.

B23

Tsimberidou, AM et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 Dec 30;12(1):145. doi: 10.1186/s13045-019-0835-1.

Ascierto, PA et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019 Feb; 5(2): 187–194. Published online 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514.

Gadgeel, S et al. (2020) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9.

B24

Chawla, A et al. Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. JCO Precis Oncol. 2018 Nov 2;2:PO.18.00074. doi: 10.1200/PO.18.00074. eCollection 2018.

B25

Arciero, V et al. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review. JAMA Netw Open. 2021 Feb 1;4(2):e2033004. doi: 10.1001/jamanetworkopen.2020.33004.

B26

Albin, N et al. Precision medicine: A major step forward in specific situations, a myth in refractory cancers? Bull Cancer. 2018 Apr;105(4):375-396. doi: 10.1016/j.bulcan.2018.01.009. Epub 2018 Mar 1.

Pathology | Misdiagnosis

C3

Swapp, RE et al. Outside case review of surgical pathology for referred patients: the impact on patient care. Arch Pathol Lab Med. 2013 Feb;137(2):233-40. doi: 10.5858/arpa.2012-0088-OA. Epub 2012 Jul 9.

Cancer and Treatment

Cancer and Financials

E10

Smith, GL et al. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. J Natl Compr Canc Netw. 2019 Oct 1;17(10):1184-1192. doi: 10.6004/jnccn.2019.7305.

E11

Yezefski, T et al. Impact of trained oncology financial navigators on patient out-of-pocket spending. Am J Manag Care. 2018 Mar;24(5 Suppl):S74-S79.

E12

Blumen, H et al. Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service. Am Health Drug Benefits. 2016 Feb;9(1):23-32.

Kakushadze, Z, et al. Estimating Cost Savings from Early Cancer Diagnosis. Data. 2017; 2(3):30. https://doi.org/10.3390/data2030030

Grady, I et al. Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis. Eur J Health Econ. 2021 May 18. doi: 10.1007/s10198-021-01315-y. Online ahead of print.

Cancer and the Workplace

Cancer and Misinformation

Cancer and Clinical Trials

Cancer and COVID-19

I1

Delay in Cancer Screening and Diagnosis During the COVID-19 Pandemic: What Is the Cost? September 21, 2020; Julie M. Vose, MD, MBA; Oncology, ONCOLOGY Vol 34 Issue 9, Volume 34, Issue 9.

Vose, Julie M. Delay in Cancer Screening and Diagnosis During the COVID-19 Pandemic: What Is the Cost? Oncology (Williston Park). 2020 Sep 15;34(9):343. doi: 10.46883/ONC.2020.3409.0343.

London JW, Fazio-Eynullayeva E, Palchuk MB, et al: Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clinical Cancer Inform. 2020;4: 657-665. doi: 10.1200/CCI.20.0006

Genomics, Cancer and DEI

Cancer and Case Management

K2

Gorin, SS et al. Cancer Care Coordination: a Systematic Review and Meta-Analysis of Over 30 Years of Empirical Studies. Ann Behav Med. 2017 Aug;51(4):532-546. doi: 10.1007/s12160-017-9876-2.

K3

Muñoz, R et al. Multidisciplinary Cancer Care Model: A Positive Association Between Oncology Nurse Navigation and Improved Outcomes for Patients With Cancer. Clin J Oncol Nurs. 2018 Oct 1;22(5):E141-E145. doi: 10.1188/18.CJON.E141-E145.

Freund KM et al. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst. 2014 Jun 17;106(6):dju115. doi: 10.1093/jnci/dju115. Print 2014 Jun.

Loiselle, CG et al. The nurse pivot-navigator associated with more positive cancer care experiences and higher patient satisfaction. Can Oncol Nurs J. 2020 Jan 1;30(1):48-53. doi: 10.5737/236880763014853.eCollection Winter 2020.

Yackzan, S et al. Outcome Measurement: Patient Satisfaction Scores and Contact With Oncology Nurse Navigators. Clin J Oncol Nurs. 2019 Feb 1;23(1):76-81. doi: 10.1188/19.CJON.76-81.

Tho PC, Ang E. The effectiveness of patient navigation programs for adult cancer patients undergoing treatment: a systematic review. JBI Database System Rev Implement Rep. 2016 Feb;14(2):295-321. doi: 10.11124/jbisrir-2016-2324.

Scherz N et al. Case management to increase quality of life after cancer treatment: a randomized controlled trial. BMC Cancer. 2017 Mar 28;17(1):223. doi: 10.1186/s12885-017-3213-9.

Genomics and Insurance

Heart Disease

Surgery | Blood Clot

Pharmacogenetics

Neurology

Births

Health Literacy

R1

Hersh, L et al. Health Literacy in Primary Care Practice. Am Fam Physician. 2015 Jul 15;92(2):118-24.

R2

Smith, SG et al. Social isolation, health literacy, and mortality risk: Findings from the English Longitudinal Study of Ageing. Health Psychol. 2018 Feb;37(2):160-169.

Medical Records Platform

Senior Health

X